We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.39B
AUM Growth
-$132M
Cap. Flow
-$296M
Cap. Flow %
-5.49%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$168M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$151M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$108M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$65.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VECT
51
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$38.8M 0.72%
6,473,561
– –
JANX icon
52
Janux Therapeutics
JANX
$1.01B
$38.4M 0.71%
2,836,386
– –
IONS icon
53
Ionis Pharmaceuticals
IONS
$7.85B
$34M 0.63%
768,900
+315,500
+70% +$13.3M
THC icon
54
Tenet Healthcare
THC
$21B
$33.2M 0.62%
643,300
-13,000
-2% -$772K
SCPH
55
DELISTED
scPharmaceuticals
SCPH
$31.3M 0.58%
4,797,148
– –
TVTX icon
56
Travere Therapeutics
TVTX
$5.89B
$30.9M 0.57%
1,253,130
+480,930
+62% +$12.4M
RAPT
57
DELISTED
RAPT Therapeutics
RAPT
$30.1M 0.56%
156,384
+48,084
+44% +$9.1M
QURE icon
58
uniQure
QURE
$2.99B
$30M 0.56%
1,597,000
+722,151
+83% +$15.2M
ALPN
59
DELISTED
Alpine Immune Sciences Inc
ALPN
$29.4M 0.55%
4,081,592
– –
ALXO icon
60
ALX Oncology
ALXO
$261M
$27.5M 0.51%
2,871,000
+684,731
+31% +$7.98M
BHVN
61
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$25.8M 0.48%
170,769
-548,265
-76% -$81.3M
TELA icon
62
TELA Bio
TELA
$48.9M
$25.8M 0.48%
3,027,542
– –
GRCL
63
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$25.4M 0.47%
7,884,870
– –
ETNB
64
DELISTED
89bio
ETNB
$21.2M 0.39%
3,658,869
– –
IOVA icon
65
Iovance Biotherapeutics
IOVA
$4.24B
$19.2M 0.36%
2,007,458
-790,983
-28% -$9.12M
GHRS icon
66
GH Research
GHRS
$1.89B
$18.8M 0.35%
1,622,060
– –
MGTX icon
67
MeiraGTx Holdings
MGTX
$1.23B
$17.7M 0.33%
2,108,143
-393,475
-16% -$3.47M
PCVX icon
68
Vaxcyte
PCVX
$8.81B
$17.2M 0.32%
717,900
-795,759
-53% -$20.2M
DBTX
69
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$17.1M 0.32%
4,945,192
– –
IVVD icon
70
Invivyd
IVVD
$245M
$16.5M 0.31%
5,270,400
+214,400
+4% +$856K
KZR
71
DELISTED
Kezar Life Sciences
KZR
$15.3M 0.28%
177,170
+35,180
+25% +$3.42M
TSVT
72
DELISTED
2seventy bio
TSVT
$15.2M 0.28%
+1,041,300
New +$15.5M
KALV
73
DELISTED
KalVista Pharmaceuticals
KALV
$15.1M 0.28%
1,042,000
+856,600
+462% +$12M
NPCE icon
74
Neuropace
NPCE
$489M
$15M 0.28%
4,012,281
– –
VSTM icon
75
Verastem
VSTM
$665M
$14.6M 0.27%
+1,433,333
New +$20M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39B, down 2.4% from $5.52B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed withdrew a net $296M in Q3 2022, closing 25 positions and reducing 31 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $168M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Third Harmonic Bio worth $110M.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168M.
  • OrbiMed's ten largest holdings make up 31% of its $5.39B portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39B.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.